Free Trial

DBV Technologies (DBVT) Stock Forecast & Price Target

+0.03 (+3.62%)
(As of 07/19/2024 ET)

DBV Technologies - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 3 Wall Street analysts who have issued ratings for DBV Technologies in the last 12 months, the stock has a consensus rating of "Hold." Out of the 3 analysts, 1 has given a sell rating, and 2 have given a buy rating for DBVT.

Consensus Price Target

676.46% Upside
High Forecast$10.00
Average Forecast$6.67
Low Forecast$2.00

According to the 3 analysts' twelve-month price targets for DBV Technologies, the average price target is $6.67. The highest price target for DBVT is $10.00, while the lowest price target for DBVT is $2.00. The average price target represents a forecasted upside of 676.46% from the current price of $0.86.

TypeCurrent Forecast
7/21/23 to 7/20/24
1 Month Ago
6/21/23 to 6/20/24
3 Months Ago
4/22/23 to 4/21/24
1 Year Ago
7/21/22 to 7/21/23
Consensus Rating
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
4 Buy rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$6.67$6.67$10.00$14.00
Forecasted Upside676.46% Upside209.02% Upside348.35% Upside335.87% Upside
Get DBV Technologies Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter.

DBVT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DBVT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

DBV Technologies Stock vs. The Competition

TypeDBV TechnologiesMedical CompaniesS&P 500
Consensus Rating Score
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside693.65% Upside3,363.24% Upside9.98% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/8/2024HC Wainwright
3 of 5 stars
 Lower TargetBuy ➝ Buy$20.00 ➝ $10.00+639.64%
11/2/2023The Goldman Sachs Group
2 of 5 stars
 Lower TargetSell ➝ Sell$2.60 ➝ $2.00
8/1/2023JMP Securities
2 of 5 stars
 Reiterated RatingMarket Outperform ➝ Market Outperform$8.00+156.41%
1/4/2023Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
8/4/2022Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Arsene Guekam
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy€12.00

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 05:56 AM ET.

DBVT Forecast - Frequently Asked Questions

What is DBV Technologies' forecast for 2024?

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for DBV Technologies is $6.67, with a high forecast of $10.00 and a low forecast of $2.00.

Should I buy or sell DBV Technologies stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last year. There is currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DBVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DBVT, but not buy additional shares or sell existing shares.

Does DBV Technologies's stock price have much upside?

According to analysts, DBV Technologies's stock has a predicted upside of 209.02% based on their 12-month stock forecasts.

What analysts cover DBV Technologies?

DBV Technologies has been rated by research analysts at HC Wainwright in the past 90 days.

Do Wall Street analysts like DBV Technologies more than its competitors?

Analysts like DBV Technologies less than other "medical" companies. The consensus rating for DBV Technologies is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DBVT compares to other companies.

This page (NASDAQ:DBVT) was last updated on 7/20/2024 by Staff

From Our Partners